Guo H F, Su H L, Mao J J, Sun C, Wang J, Zhou X
Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, P.R. China.
Int J Clin Pharmacol Ther. 2010 Nov;48(11):776-8. doi: 10.5414/cpp48776.
Thromboembolic complications commonly occur in patients with multiple myeloma (MM). The risk of such complications may be elevated by the use of immunomodulatory agents such as thalidomide and lenalidomide as initial therapy for MM. However, arterial thrombosis after treatment with bortezomib is rare. Herein we report a case of a 70-year-old Chinese male patient with extramedullary relapse of MM. After treatment with bortezomib and dexamethasone he developed a nonfatal thrombotic stroke. Administration of bortezomib and dexamethasone was then discontinued and he obtained partial remission.
血栓栓塞并发症在多发性骨髓瘤（MM）患者中很常见。使用沙利度胺和来那度胺等免疫调节剂作为MM的初始治疗可能会增加此类并发症的风险。然而，硼替佐米治疗后发生动脉血栓形成的情况很少见。在此，我们报告一例70岁中国男性MM髓外复发患者。在接受硼替佐米和地塞米松治疗后，他发生了非致命性血栓性中风。随后停用硼替佐米和地塞米松，他获得了部分缓解。
